Insights from native mass spectrometry approaches for top- and middle- level characterization of site-specific antibody-drug conjugates

被引:54
作者
Botzanowski, Thomas [1 ]
Erb, Stephane [1 ]
Hernandez-Alba, Oscar [1 ]
Ehkirch, Anthony [1 ]
Colas, Olivier [2 ]
Wagner-Rousset, Elsa [2 ]
Rabuka, David [3 ]
Beck, Alain [2 ]
Drake, Penelope M. [3 ]
Cianferani, Sarah [1 ]
机构
[1] Univ Strasbourg, CNRS, Lab Spectrometrie Masse BioOrgan, Strasbourg, France
[2] Ctr Immunol Pierre Fabre, St Julien En Genevois, France
[3] Catalent Biol West, Emeryville, CA USA
关键词
Antibody-drug conjugate (ADC); ion mobility-mass spectrometry (IM-MS); middle level; native mass spectrometry; site-specific bioconjugation; top level; NEXT-GENERATION; CANCER-THERAPY; ALDEHYDE TAGS; GLYCOSYLATION; COPPER(II); CHALLENGES; STABILITY; COMPLEXES; LIGATION; PROTEINS;
D O I
10.1080/19420862.2017.1316914
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Antibody-drug conjugates (ADCs) have emerged as a family of compounds with promise as efficient immunotherapies. First-generation ADCs were generated mostly via reactions on either lysine side-chain amines or cysteine thiol groups after reduction of the interchain disulfide bonds, resulting in heterogeneous populations with a variable number of drug loads per antibody. To control the position and the number of drug loads, new conjugation strategies aiming at the generation of more homogeneous site-specific conjugates have been developed. We report here the first multi-level characterization of a site-specific ADC by state-of-the-art mass spectrometry (MS) methods, including native MS and its hyphenation to ion mobility (IM-MS). We demonstrate the versatility of native MS methodologies for site-specific ADC analysis, with the unique ability to provide several critical quality attributes within one single run, along with a direct snapshot of ADC homogeneity/heterogeneity without extensive data interpretation. The capabilities of native IM-MS to directly access site-specific ADC conformational information are also highlighted. Finally, the potential of these techniques for assessing an ADC's heterogeneity/homogeneity is illustrated by comparing the analytical characterization of a site-specific DAR4 ADC to that of first-generation ADCs. Altogether, our results highlight the compatibility, versatility, and benefits of native MS approaches for the analytical characterization of all types of ADCs, including site-specific conjugates. Thus, we envision integrating native MS and IM-MS approaches, even in their latest state-of-the-art forms, into workflows that benchmark bioconjugation strategies.
引用
收藏
页码:801 / 811
页数:11
相关论文
共 40 条
[1]   Hydrazino-Pictet-Spengler Ligation as a Biocompatible Method for the Generation of Stable Protein Conjugates [J].
Agarwal, Paresh ;
Kudirka, Romas ;
Albers, Aaron E. ;
Barfield, Robyn M. ;
de Hart, Gregory W. ;
Drake, Penelope M. ;
Jones, Lesley C. ;
Rabuka, David .
BIOCONJUGATE CHEMISTRY, 2013, 24 (06) :846-851
[2]   Exploring the effects of linker composition on site-specifically modified antibody-drug conjugates [J].
Albers, Aaron E. ;
Garofalo, Albert W. ;
Drake, Penelope M. ;
Kudirka, Romas ;
de Hart, Gregory W. ;
Barfield, Robyn M. ;
Baker, Jeanne ;
Banas, Stefanie ;
Rabuka, David .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2014, 88 :3-9
[3]   Synthesis of site-specific antibody-drug conjugates using unnatural amino acids [J].
Axup, Jun Y. ;
Bajjuri, Krishna M. ;
Ritland, Melissa ;
Hutchins, Benjamin M. ;
Kim, Chan Hyuk ;
Kazane, Stephanie A. ;
Halder, Rajkumar ;
Forsyth, Jane S. ;
Santidrian, Antonio F. ;
Stafin, Karin ;
Lu, Yingchun ;
Hon Tran ;
Seller, Aaron J. ;
Biroce, Sandra L. ;
Szydlik, Aga ;
Pinkstaff, Jason K. ;
Tian, Feng ;
Sinha, Subhash C. ;
Felding-Habermann, Brunhilde ;
Smider, Vaughn V. ;
Schultz, Peter G. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (40) :16101-16106
[4]  
Beck A, 2017, NAT REV DRU IN PRESS
[5]   Cutting-edge mass spectrometry methods for the multi-level structural characterization of antibody-drug conjugates [J].
Beck, Alain ;
Terral, Guillaume ;
Debaene, Francois ;
Wagner-Rousset, Elsa ;
Marcoux, Julien ;
Janin-Bussat, Marie-Claire ;
Colas, Olivier ;
Van Dorsselaer, Alain ;
Cianférani, Sarah .
EXPERT REVIEW OF PROTEOMICS, 2016, 13 (02) :157-183
[6]   Antibody-drug conjugates Present and future [J].
Beck, Alain ;
Reichert, Janice M. .
MABS, 2014, 6 (01) :15-17
[7]  
Beck Alain, 2012, MAbs, V4, P637, DOI 10.4161/mabs.21697
[8]   Strategies and challenges for the next generation of therapeutic antibodies [J].
Beck, Alain ;
Wurch, Thierry ;
Bailly, Christian ;
Corvaia, Nathalie .
NATURE REVIEWS IMMUNOLOGY, 2010, 10 (05) :345-352
[9]   Collision Cross Sections of Proteins and Their Complexes: A Calibration Framework and Database for Gas-Phase Structural Biology [J].
Bush, Matthew F. ;
Hall, Zoe ;
Giles, Kevin ;
Hoyes, John ;
Robinson, Carol V. ;
Ruotolo, Brandon T. .
ANALYTICAL CHEMISTRY, 2010, 82 (22) :9557-9565
[10]   Efficient Payload Delivery by a Bispecific Antibody-Drug Conjugate Targeting HER2 and CD63 [J].
de Goeij, Bart E. C. G. ;
Vink, Tom ;
ten Napel, Hendrik ;
Breij, Esther C. W. ;
Satijn, David ;
Wubbolts, Richard ;
Miao, David ;
Parren, Paul W. H. I. .
MOLECULAR CANCER THERAPEUTICS, 2016, 15 (11) :2688-2697